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ABSTRACT
Multidrug resistance–associated protein 3 (Mrp3; Abcc3) expres-
sion and activity are up-regulated in rat liver after in vivo
repeated administration of ethynylestradiol (EE), a cholestatic
synthetic estrogen, whereas multidrug resistance-associated
protein 2 (Mrp2) is down-regulated. This study was undertaken
to determine whether Mrp3 induction results from a direct effect
of EE, independent of accumulation of any endogenous common
Mrp2/Mrp3 substrates resulting from cholestasis and the poten-
tial mediation of estrogen receptor (ER). In in vivo studies, male
rats were given a single, noncholestatic dose of EE (5 mg/kg s.c.),
and basal bile flow and the biliary excretion rate of bile salts and
glutathione were measured 5 hours later. This treatment in-
creased Mrp3 mRNA by 4-fold, detected by real-time polymerase
chain reaction, despite the absence of cholestasis. Primary
culture of rat hepatocytes incubated with EE (1–10 mM) for 5
hours exhibited a 3-fold increase in Mrp3 mRNA (10 mM),
consistent with in vivo findings. The increase in Mrp3 mRNA by
EE was prevented by actinomycin D, indicating transcriptional
regulation. When hepatocytes were incubated with an ER
antagonist [7a,17b-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]
estra-1,3,5(10)-triene-3,17-diol (ICI182/780), 1 mM], in addition to
EE, induction of Mrp3 mRNA was abolished, implicating ER as
a key mediator. EE induced an increase in ER-a phosphorylation
at 30 minutes and expression of c-Jun, a well-known ER target
gene, at 60 minutes, as detected by Western blotting of nuclear
extracts. These increases were prevented by ICI182/780. In
summary, EE increased the expression of hepatic Mrp3 tran-
scriptionally and independently of any cholestatic manifestation
and required participation of an ER, most likely ER-a, through its
phosphorylation.
Introduction
Multidrug resistance–associated protein 3 (Mrp3; ABCC3), is
expressed in different cell types, including hepatocytes, where it is
localized to the basolateral membrane (König et al., 1999a). Mrp3
extrudes anionic substrates, such as sulfated bile salts, bilirubin
glucuronides, 17b-glucuronosyl estradiol, and some anticancer drugs
(König et al., 1999b; Kool et al., 1999; Hirohashi et al., 2000). In
normal conditions, these substrates are preferentially excreted across
the apical domain into the canaliculus via multidrug resistance-
associated protein 2 (Mrp2; ABCC2). The extent of constitutive Mrp3
expression is normally low in rats but is markedly up-regulated in
Mrp2-deficient rats (Johnson et al., 2006) and in rats with obstructive
cholestasis (Donner and Keppler 2001; Soroka et al., 2001). Human
Mrp3 was also found to be inducible, as shown in patients with Dubin-
Johnson syndrome (König et al., 1999b). As a result, this transporter
has been postulated to protect the liver by extruding bilirubin and bile
salt conjugates from the hepatocytes when bile secretion is impaired.
Estrogens are involved in the pathogenesis of both oral
contraceptive–induced cholestasis and cholestasis of pregnancy (Vore
1987; Reyes and Simon 1993). Ethynylestradiol (EE), a synthetic
estrogen, is known to reduce bile flow after chronic treatment in experi-
mental animals. In the rat, decreased bile flow after EE administration
(5 mg/kg body weight for 5 consecutive days) has been associated with
decreased expression and activity of Mrp2 (Trauner et al., 1997; Lee
et al., 2000). We demonstrated that Mrp3 is up-regulated in liver from
EE-induced cholestatic rats (Ruiz et al., 2006, 2007), but the mech-
anisms involved remain uncertain. In other models of cholestasis, such
as in bile duct ligated or lipopolysaccharide-treated rats, accumulation
of common endogenous Mrp2/Mrp3 substrates or increased production
of cytokines, such as tumor necrosis factor-a or interleukin-6, have
been proposed to be responsible for Mrp3 up-regulation (Ogawa
et al., 2000; Bohan et al., 2003; Vee et al., 2009). We previously
reported that spironolactone counteracted the decrease in bile flow and
biliary excretion of the Mrp2 substrates glutathione and acetaminophen-
glucuronide in EE-treated cholestatic rats through up-regulation of
Mrp2 (Ruiz et al., 2007). Rats treated simultaneously with spironolactone
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and EE exhibit up-regulation of both Mrp2 and Mrp3 (Ruiz et al., 2007)
and are not cholestatic, implying that accumulation of endogenous Mrp2/
Mrp3 substrates is unlikely to be responsible for Mrp3 up-regulation. We
hypothesized that a more direct action of EE on Mrp3 gene regulation is
involved.
The physiologic actions of estrogens are mediated by estrogen
receptors (ER)–a and b, belonging to the superfamily of steroids/
nuclear receptors (Kuiper et al., 1996). Various aspects of ER-a
transcriptional activation are dependent on phosphorylation of the
receptor. Coactivator recruitment, subcellular localization, receptor
dimerization, ligand binding, and posttranslational modifications are
regulated through the phosphorylation of individual sites of ER-a
(Williams et al., 2009). Mutations of Ser118 to alanine caused, in a
number of cell types, a significant reduction in transcriptional activation
by ER from reporter gene containing estrogen response elements, with
no effect on DNA binding properties or nuclear localization of ER
(Ali et al., 1993). The liver expresses predominantly ER-a (Alvaro
et al., 2000), and its expression is under multi-hormonal regulation.
By using knockout mice, Yamamoto et al. (2006) demonstrated that
ER-a mediates the repression of hepatic transporters and alterations
of bile acid biosynthesis, contributing to development of EE-induced
cholestasis/hepatotoxicity. It is not known, however, whether ER
activation is responsible for Mrp3 up-regulation.
In the present study, we investigated whether a direct action of EE,
requiring participation of an ER, is involved in up-regulation of Mrp3
in the rat. The data indicate that ER-a likely mediates transcriptional
Mrp3 up-regulation in response to EE treatment and that this can occur
in the absence of cholestasis.
Materials and Methods
Chemicals. EE, leupeptin, phenylmethylsulfonyl fluoride, glutathione,
glutathione reductase, 3a-hydroxysteroid dehydrogenase, b-nicotinamide
adenine dinucleotide, and NADPH were obtained from Sigma-Aldrich (St.
Louis, MO). All other chemicals were of analytical grade purity and used as
supplied.
Animals. Adult male Wistar rats weighing 300–350 g were used. They had
free access to food and water and were maintained on an automatically timed
12-hour light/12-hour dark cycle. All procedures involving animals were
conducted in accordance with the National Institutes of Health Guidelines for
the Care and Use of Laboratory Animals.
In Vivo Experiments: Administration of a Single Dose of EE and
Assessment of Biliary Secretory Function. Rats were randomly divided in
two experimental groups (n = 5). EE-treated rats were administered EE at
a single dose of 5 mg/kg body weitht subcutaneously, equivalent to the first
dose of the usual cholestatic protocol (Trauner et al., 1997). EE was dissolved
in propylene glycol as a vehicle at a final concentration of 33.7 mM. Control
rats were injected with propylene glycol (0.5 ml/kg body weight sub-
cutaneously). Five hours later, bile was collected for determination of bile flow
and biliary excretion of bile salts and glutathione as described (Ruiz et al.,
2005). At the end of the collection period, animals were sacrificed by
exsanguination, the livers removed, washed with cold saline, and snap frozen in
liquid nitrogen and preserved at 270°C until use for total RNA isolation.
In Vitro Experiments: Isolation, Culture, and Treatment of Rat
Hepatocytes. Hepatocytes were isolated from normal livers of male Wistar
rats by collagenase perfusion and mechanical disruption (Seglen, 1973). Cell
viability, assessed by trypan blue exclusion, was greater than 86%. Freshly
isolated hepatocytes were plated onto collagen-coated glass plates at 3.8  104
cells/cm2, containing Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and
streptomycin (100 mg/ml) (Invitrogen, Carlsbad, CA). Cells were incubated at
37°C in a humidified atmosphere of 5% CO2 for 3 hours, allowing cell
attachment. Media then were changed to new media containing DMEM phenol
red-free supplemented with 10% charcoal-dextran treated FBS (Hyclone
Laboratories, Logan, UT), penicillin (100 U/ml), and streptomycin (100 mg/ml)
(Invitrogen), and hepatocytes were incubated for 5 hours in the presence of EE
(1, 10, or 100 mM) or its vehicle (DMSO 0.08% v/v). In some incubations, cells
were pretreated for 30 minutes with 5 mg/ml actinomycin D (Fluka, St. Louis,
MO). Alternatively, cells were pretreated for 30 minutes with the ER antagonist
7a,17b-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-
3,17-diol (ICI182/780, 1 mM) (Tocris Cookson Inc., Ellisville, MO) before
the addition of EE. The inhibitors were present during the treatment with EE.
At the end of the incubation period, total RNA was prepared for real-time
polymerase chain reaction (PCR) analysis. In a different set of incubations,
cells were incubated with ICI182/780 (1 mM) for 30 minutes and then with EE
(10 mM) for 30, 60, or 120 minutes. At the end of incubation periods, cells
were harvested to prepare nuclear extracts.
None of the treatments affected cell viability (data not shown), as determined
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltretazoliumbromide assay (Rigalli
et al., 2011), when EE was added to incubations at a 1 or 10 mM concentration.
Addition of EE at a 100 mM concentration induced a significant decrease in cell
viability, and thus, this concentration was not further used in subsequent
experiments.
Quantitative Real-Time PCR and Western Blot Studies. Total RNA was
isolated from liver samples or cultured hepatocytes with use of TRIzol
(Invitrogen), according to the manufacturer’s protocol. Real-time PCR was
performed on a Mx3000P System (Stratagene, La Jolla, CA) with use of the
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen), as described
previously (Rigalli et al., 2011). Sequences of primer pairs for rat Mrp3,
Mrp2, and 18S and reaction conditions were as previously described (Ruiz
et al., 2007).
Phosphorylation of ER-a was studied by Western blotting of nuclear extracts.
In brief, cultured hepatocytes were washed with ice-cold PBS and scrapped
with sucrose 0.3 M and protease inhibitors (35 nM leupeptin and 0.1 mM
phenylmethylsulfonyl fluoride) and phosphatase inhibitor cocktail (1/100 v/v;
Sigma-Aldrich). After sonicating the samples, they were centrifuged at 1000g for
10 minutes at 4°C.The pellets then were washed twice with 0.3 M sucrose and
protease and phosphatase inhibitors and centrifuged at 1000g for 10 minutes. The
nuclei-enriched pellets were lysed with radioimmunoprecipitation assay buffer for
1 hour at 4°C and centrifuged for 15 minutes at 8000g. Supernatants were
subjected to protein concentration determination (Sedmak and Grossberg, 1977)
and 12% SDS-polyacrylamide gel electrophoresis. Western blot analysis was
performed as described elsewhere (Ruiz et al., 2005), using anti-phospho-ER-a
(Ser118), anti-ER-a, and anti-histone (SC-12915, H-184 and AE-4, respectively;
Santa Cruz Biotechnology Inc., Santa Cruz, CA). The effect of EE on expression
of c-Jun, a known ER target gene (Hyder et al., 1995), was also examined. Nuclear
extracts were obtained as described above, and c-Jun expression was evaluated by
Western blotting using anti-c-Jun (SC-1694; Santa Cruz Biotechnology Inc.), as
described elsewhere (Ruiz et al., 2005).
TABLE 1
Effect of EE on markers of cholestasis
Rats were injected with a single dose of EE (5 mg/kg s.c. body weight) or vehicle (control), and bile and serum samples were collected 5
hours later. Data represent mean 6 S.D. (n=5).
Marker Control EE
Bile flow (ml/min g liver) 1.40 6 0.14 1.35 6 0.19
Biliary excretion of total bile salts (nmol/min g liver) 50 6 6 47 6 5
Biliary excretion of total glutathione (nmol/min g liver) 2.00 6 0.79 1.80 6 0.72
Serum ALP activity (U/l) 256 6 10 269 6 12
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Statistical Analysis. Results are expressed as mean 6 S.D. Statistical
analysis was performed using Student’s t test or one-way analysis of variance,
followed by Newman Keuls test. Values of P , 0.05 were considered to be
statistically significant.
Results
Mrp3 Up-Regulation by EE Is Independent of Cholestasis and
Mediated by ER. To determine whether the effect of EE is independent
of cholestasis and the consequent accumulation of endogenous Mrp2/Mrp3
substrates, two different experiments were performed. As a first approach,
basal bile flow, biliary excretion of total bile salts and glutathione, and
serum alkaline phosphatase were measured 5 hours after a single dose of
EE. These cholestatic markers remained unchanged when compared with
vehicle-treated controls (Table 1), indicating that cholestasis was not yet
established. Under this condition, we observed that the levels of hepatic
Mrp3 mRNA were increased by 330% (Fig. 1A), to a similar extent as
previously reported after repeated administration with EE (Ruiz et al.,
2007). As a second approach, primary culture of rat hepatocytes was used
as an experimental model. We found that 10 mM EE produced an increase
in Mrp3 mRNA (350%) (Fig. 1B) similar to that found in vivo, whereas
1 mM EE induced no changes. As a negative control, we evaluated Mrp2
mRNA levels and found no changes at either 1 or 10 mM EE (Fig. 1B).
To study the mechanism involved in the induction of Mrp3 mRNA
levels, we used the RNA polymerase II inhibitor actinomycin D. Fig.
1C shows that the action of EE on Mrp3 expression in primary culture
of hepatocytes was prevented by actinomycin D, providing support for
the transcriptional effect of the estrogen.
To evaluate whether ER mediates the action of EE, we measured
Mrp3 mRNA expression in the presence or absence of ICI 182/780
and found that Mrp3 mRNA up-regulation was abolished in the
presence of the ER antagonist (Fig. 1D). Further analysis of ER-a
phosphorylation by Western blotting of nuclear extracts at 30, 60, or
120 minutes after addition of EE to the culture medium showed
increased detection of phospho-ER-a at 30 minutes but not at 60 or
120 minutes (Fig. 2A). Increased phosphorylation of ER-a by EE was
absent when culture cells were preincubated with ICI182/780 (Fig.
2B). The two bands for phospho-ER-a likely represent degrees of
phosphorylation and/or alternative sites of phosphorylation different
from Ser118 and were quantified together. The total levels of nuclear
ER remained unchanged among groups.
To further implicate ER in up-regulation of Mrp3 mRNA expression
observed under current experimental conditions, we evaluated the effect of
EE on the expression of c-Jun, a well-known ER target gene (Hyder et al.,
1995). We found an increase in c-Jun protein expression at the same EE
concentration able to increase Mrp3 mRNA levels (Fig. 3A). This effect
was evident as early as 60 minutes after addition of EE to the culture
medium (Fig. 3B). Induction of c-Jun expression was also prevented by
ICI182/780 (data not shown).
Discussion
Various studies have shown that EE decreases Mrp2 and increases
Mrp3 expression in rat liver (Trauner et al., 1997; Lee et al., 2000;
Kamisako and Ogawa, 2005; or Ruiz et al., 2006). Under cholestatic
conditions, down-regulation of Mrp2 leads to intrahepatic accumula-
tion of its substrates, such as bilirubin conjugates and conjugated bile
salts. These substrates, common to other Mrps, are postulated to act as
Fig. 1. Effect of EE on Mrp3 mRNA expression. (A) In vivo studies: analysis of
RNA obtained from liver of rats 5 hours after administration of a single 5 mg/kg body
weight dose of EE. (B) In vitro studies: analysis of RNA obtained from primary culture
of hepatocytes incubated with EE (1 or 10 mM) for 5 hours. Mrp3 and Mrp2 mRNA
levels were detected by real-time PCR. (C) Analysis of RNA obtained from cultured
hepatocytes incubated with actinomycin D (ActD) for 30 minutes and with EE (10
mM) for 5 hours. (D) Analysis of RNA obtained from cultured hepatocytes incubated
with ICI182/780 for 30 minutes and with EE (10 mM) for 5 hours. Mrp3 mRNA levels
were detected by real-time PCR. Data are presented as a percentage of control (C;
100%) and were expressed as means6 S.D. (n = 5). Statistical analysis was performed
using Student’s t test (A) or one-way analysis of variance, followed by Newman Keuls
test (B and C). Values of P , 0.05 were considered to be statistically significant. 18S
rRNA was used as internal control. a: significantly different from (C), P , 0.05. b:
significantly different from EE 1 mM, P , 0.05. c: significantly different from EE 10
mM, P , 0.05.
Estrogen Receptor Mediates Mrp3 Induction by Ethynylestradiol 277
 at A
SPET Journals on January 28, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
inducers of Mrp3 (Ogawa et al., 2000). However, the present data,
based on results after administration of a single, noncholestatic dose
of EE to rats, showed an increase in Mrp3 mRNA expression within
5 hours, suggesting a more direct regulation of Mrp3 gene. This
hypothesis is further supported by a similar induction of Mrp3 mRNA
in primary cultures of rat hepatocytes, where conjugated bilirubin, a
potential inducer of Mrp3, is absent. We cannot rule out the possibility
that additional endogenous compounds (e.g., newly synthesized bile
salts) participate in the regulation of Mrp3 mRNA. However, we
found, in this same model, that an ER inhibitor prevented Mrp3
mRNA up-regulation, further supporting a causal EE-ER interaction.
This induction was observed at a 10 mM concentration of EE. The
volume of distribution for EE in rats was estimated to be 2 l/kg (Zamek-
Gliszczynski et al., 2011), and in consequence, a concentration of EE
of 10 mM would be compatible with administration of a 5–6 mg/kg
birth weight dose of EE, which is equivalent to the single dose currently
administered in vivo. ER-a was also implicated in repression of
hepatic transporters and alteration of bile acid biosynthesis using
a dose of EE that is even higher than the dose commonly used in rats
(Yamamoto et al., 2006). Although the observed increase in mRNA
levels after 5 hours of treatment in vivo and in hepatocytes might
be caused by ER as a common mediator, further studies would be
necessary to demonstrate that the increased Mrp3 mRNA levels
occurring in the isolated hepatocytes model results in induction of
Mrp3 protein, as previously seen after repeated treatment in vivo
(Ruiz et al., 2007).
The data from actinomycin D experiments indicate that Mrp3 was
transcriptionally up-regulated by EE. Similar experiments in the
presence of the ER antagonist ICI182/780 unambiguously demon-
strate the participation of an ER in Mrp3 up-regulation. ER-a is the
predominant ER subtype present in liver (Alvaro et al., 2000), and its
activation by ligand can regulate genes by either a transcriptional or
a posttranscriptional manner (i.e., mRNA stabilization) (Ing, 2005). In
addition, it is well demonstrated that ER-a becomes predominantly
phosphorylated on Ser118 in response to treatment with estradiol,
which further results in increased association with known ER-a
coactivators (Lannigan, 2003). Our data demonstrate increased phos-
phorylation of ER-a by EE, as detected in the nucleus of cultured
hepatocytes. Of interest, preincubation of the cells with an ER
antagonist, shown to prevent induction of Mrp3 (Fig. 1), was also
able to prevent ER-a phosphorylation (Fig. 2) and induction of the
expression of c-Jun, a well-known ER target gene. Taken together,
these findings suggest that EE induces ER-a phosphorylation,
followed by transcriptional regulation of Mrp3.
ER regulates transcription processes through its binding to the ER
element in the promoter region (classic way). Alternatively, many
Fig. 2. Effect of EE on nuclear content of phospho-ER-a (Ser118) in cultured hepatocytes. (A) Hepatocytes were incubated with EE (10 mM; 30, 60, or 120 minutes) or
vehicle (C, control). (B) Hepatocytes were preincubated with ICI182/780 (1 mM; 30 minutes) and with EE (10 mM; 30, 60, or 120 minutes). Equal amounts of nuclear extract
protein (15 mg) were loaded in all lanes. Uniformity of protein loading and transfer from gel to nitrocellulose membrane were controlled with Ponceau S and histone
detection. Densitometric analyses were performed separately for phospho-ER-a and for total ER-a, and the phospho-ER-a/ER-a densitometry ratio was calculated and
expressed as means 6 S.D. (n = 4). Statistical analysis was performed using one-way analysis of variance, followed by Newman Keuls test. Values of P , 0.05 were
considered to be statistically significant. a: significantly different from C, 60 minutes and 120 minutes, P , 0.05.
278 Ruiz et al.
 at A
SPET Journals on January 28, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
estrogen-responsive genes are regulated by sequences that are not
bound directly by ER, such as activating protein-1 (AP-1) and
specificity protein–1 binding sites (Marino et al., 2006). To gain
insight into the mechanisms mediating Mrp3 induction by EE, we
performed an in silico analysis using the TFSEARCH database
(http://www.cbrc.jp/research/db/TFSEARCH.html). We could not
identify any ER element in the Mrp3 promoter sequence. However,
the analysis located several binding sites for AP-1 and for
specificity protein–1 for Mrp3 gene, suggesting an indirect action
of the ER-a involving these transcription factors. Of interest, EE
induced an increase in the expression of c-Jun, a major component
of AP-1, at the same concentration that could induce Mrp3 mRNA.
Further studies are necessary to implicate c-Jun or an alternative
transcription factor in Mrp3 induction by EE downstream ER
activation.
Altered disposition of compounds that are common substrates for
Mrp2 and Mrp3 could result from differential modulation of both
transporters. In this regard, the preferential biliary versus basolateral
disposition of acetaminophen-glucuronide observed in normal rats is
reversed in rats treated with EE because of simultaneous up-regulation
of Mrp3 and down-regulation of Mrp2 (Ruiz et al., 2007). In addition,
Mrp3 exhibits a higher affinity for acetaminophen-glucuronide than
does Mrp2 (Xiong et al., 2000; Manautou et al., 2005). Our current
data clearly demonstrate that EE can induce Mrp3 in the absence of
any cholestatic manifestations. It is not known whether human
hepatic Mrp3 is induced by EE at the pharmacological doses used in
oral contraceptive treatment. However, in earlier studies, women
taking oral contraceptive steroids demonstrated a greater plasma
clearance of acetaminophen together with increased elimination of
acetaminophen-glucuronide in urine (Miners et al., 1983). The
induction of Mrp3 might lead to increased basolateral rather than
canalicular excretion of acetaminophen glucuronide, thus leading to
increased urinary excretion of this metabolite. In conclusion, the
present data demonstrate, for the first time to our knowledge, that
induction of Mrp3 by EE in rat liver is independent of cholestasis
and occurs via activation of ER.
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Fig. 3. Concentration- and time-dependent effect of EE on expression of c-Jun in
cultured hepatocytes. (A) Hepatocytes were incubated with EE (1 or 10 mM for 5
hours) or vehicle (C, control). a: significantly different from C and 1 mM P , 0.05.
(B) Hepatocytes were incubated with EE (10 mM for 30, 60, 120, or 300 minutes) or
vehicle (C). a: significantly different from C and 30 minutes, P , 0.05. Equal
amounts of nuclear extract protein (15 mg) were loaded in all lanes. Uniformity of
protein loading and transfer from gel to nitrocellulose membrane were controlled
with Ponceau S and histone detection. Data were expressed as means6 S.D. (n = 4).
Statistical analysis was performed using one-way analysis of variance, followed by
Newman Keuls test. Values of P , 0.05 were considered to be statistically
significant.
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